Global Immune Checkpoint Inhibitors Market – Size, Share and Forecast (2018-2025)

SKU: DPH19 | Published On: 2019-04-09 | Available Formats

Immune Checkpoint Inhibitors

  • Global Immune checkpoint inhibitors market is the emerging market, and it is expected to grow at CAGR of XX% during the period (2018-2025).
  • Immune checkpoint inhibitors are drugs or drug candidates, which block/inhibit the inhibitory checkpoint molecules, often referred to as checkpoint blockade. Immune checkpoint inhibitors are used for the treatment of various types of cancers including melanoma, lung cancer, blood cancer, renal cell carcinoma, squamous cell carcinoma, urothelial carcinoma, and colorectal cancer.
  • The U.S. Food and Drug Administration (FDA) has recently approved five immune checkpoint inhibitor drugs viz. ipilimumab (Yervoy®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), nivolumab (Bavencio®), and mepolizumab (Tecentriq®).

Market Drivers and Restraints:

  • The immune checkpoint inhibitors market is driven by the number of research developments undertaken by industry contributors as well as academic institutes.
  • The immune checkpoint inhibitors market is experiencing a lot of collaborations wherein companies are combining their core competencies to fasten their research programs.

Segmentation by Geography

  • Geographically, North America was the largest market for immune checkpoint inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of cancer.
  • The U.S. contributed most substantial revenue to the North American immune checkpoint inhibitors market, and it is expected to remain the most significant market globally, during the forecast period.
  • The pharmaceutical companies are actively involved in the research and development of a drug for immune checkpoint inhibitors. The pipeline of immune checkpoint inhibitors is rich with more than 50 drugs.

Market Segmentation:

By Drug Type:

  • Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti-CTLA-4 drug), the first drug to be launched in this domain, is currently being mirrored by other various medicines such as Opdivo, Keytruda (both anti-PD-1 drugs) and many under clinical development.
  • Also, numerous clinical trials are being carried out for combination therapy regarding PD-1 inhibitors across the globe. Revenue share of PD-1 inhibitors will remain considerably more extensive than all the other drug class available in the market during the forecast period.

Key market segments covered

By Drug Type

  •  HVAC CLTA-4 Inhibitors
  •  PD-1 & PD-L1 Inhibitor
  •  Others

By Application

  •  Lung cancer
  •  Renal cancer
  •  Blood cancer
  •  Bladder cancer
  •  Hodgkin lymphoma
  •  Melanoma
  •  Others

By Region

  •  Asia Pacific
  •  Europe
  •  North America
  •  South America
  •  Rest of the World
Why purchase the report?
  •  Identify commercial opportunities in Global Immune checkpoint inhibitors market by analyzing trends and co-development deals.
  •  Excel data sheet with thousands of data points of the Global Immune checkpoint inhibitors market by segmentation level.
  •  PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  •  Product mapping in excel for the critical Immune checkpoint inhibitors of all major market players.
Target Audience
  •  Raw Material Suppliers/ Buyers
  •  Product Suppliers/ Buyers
  •  Industry Investors/Investment Bankers
  •  Education & Research Institutes
  •  Research Professionals
  •  Emerging Companies
  •  Manufacturers

1. Methodology and Scope

1.1 Research methodology
1.2 Scope of the report

2. Executive Summary
3. Industry analysis

3.1 Market Drivers
3.2 Market Restraints
3.3 Porters five force analysis
3.3.1 Buyers power
3.3.2 Supplier Power
3.3.3  Industry competition
3.3.4 Threat of New Entrant
3.3.5 Threat of Substitutes

4. Market Segmentation

4.1 By Drug  Type
4.1.1 CLTA-4 Inhibitors
4.1.2 PD-1 & PD-L1 Inhibitor
4.1.3 Others
4.2 By Application
4.2.1 Lung Cancer
4.2.2 Renal Cancer
4.2.3 Bladder Cancer
4.2.4 Blood Cancer
4.2.5 Melanoma Cancer
4.2.6 Hodgkin Lymphoma

5. Geography Analysis

5.1 Asia Pacific
5.1.1 India
5.1.2 China
5.1.3 Japan
5.1.4 Korea
5.1.5 Rest of Asia Pacific
5.2 North America
5.2.1 US
5.2.2 Canada
5.2.3 Mexico
5.2.4 Rest of North America
5.3 South America
5.3.1 Argentina
5.3.2 Brazil
5.3.3 Rest of South America
5.4 Europe
5.4.1 UK
5.4.2 Germany
5.4.3 France
5.4.4 Italy
5.4.5 Rest of Europe
5.5 Rest of World

6. Competitive Landscape

6.1 Market Share Analysis
6.2 Key Strategies Adopted by Major Players
6.3 Product Benchmarking

7. Company profiles

7.1 Bristol-Myers Squibb Company
7.2 AstraZeneca Plc
7.3 Merck & Co.,
7.4 Pfizer, Inc.,
7.5 F. Hoffmann-La Roche Ltd.,
7.6 Incyte Corporation
7.7 NewLink Genetics Corporation
7.8 Celldex Therapeutics, Inc.,
7.9 GlaxoSmithKline plc.,
7.10 Seattle Genetics, Inc.

8. Global Immune checkpoint inhibitors market – Appendix

8.1 Sources
8.2 List of Tables
8.3 Expert Panel Validation
8.4 Disclaimer
8.5 Contact Us

 

Buy This Report



To get the free report sample tailored to your requirements

Could not find what you need?

Quick Fact: 7 of 10 customers Tailor their reports

DMI Cognizance Expertise

Massive Repository

10-year historic data for 1000+ markets

Association Networks

Ground-Zero understanding of the market with inputs from relevant industry association members

First Hand Understanding

Tailored interviews with manufacturers, buyers, sellers, distributers and retailers for five-frame understanding of the market

360 Web Research

Analysis of publicly available white label papers, news announcements, press releases, financial reports and reliable paid consulting data

Star Expert Review

7-step data formulation for market analysis and forecasts, under thorough scrutiny of industry-specific consultants with over 20+ years of expertise

INSTANT DELIVERY - 20% OFF

Copyright © 2019 DataM Intelligence. All Rights Reserved

Designed and Developed by -Montaigne Labs